U.S. Markets closed

United Therapeutics Corporation (UTHR)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
118.3400-2.66 (-2.20%)
At close: 4:00PM EDT

118.3542 0.01 (0.01%)
After hours: 4:41PM EDT

People also watch
ALXNBMRNVRTXMDCOMYGN

United Therapeutics Corporation

1040 Spring Street
Silver Spring, MD 20910
United States
301-608-9292
http://www.unither.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees750

Key Executives

NameTitlePayExercisedAge
Dr. Martine A. Rothblatt Ph.D., J.D., M.B.A.Founder, Chairman and Chief Exec. Officer2.23M16.5M62
Mr. Michael I. BenkowitzPres and Chief Operating Officer1.27MN/A45
Mr. James C. EdgemondChief Financial Officer and Treasurer972.46kN/A49
Mr. Paul A. Mahon J.D.Exec. VP, Gen. Counsel and Corp. Sec.1.38MN/A53
Dr. Roger A. Jeffs Ph.D.Sr. Advisor6.52MN/A55
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Corporate Governance

United Therapeutics Corporation’s ISS Governance QualityScore as of May 1, 2017 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.